Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques
- Abbreviated Name
- Lung CARET
- Lead Investigator
- Hanash, Samir — The University of Texas MD Anderson Cancer Center
- Coordinating Investigator
- Zheng, Yingye — Fred Hutchinson Cancer Center
- Involved Investigators
Abstract
To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
Aims
Aim 1: To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis. Aim 2: To identify additional antigens and antibodies in sera from CARET participants, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, and histologic type. Aim 3: To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
Analytic Method
Natural Array technique
Outcome
To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.
Publications
- Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.
Biomarkers
- 14-3-3 theta
- Annexin 1 and SOX2
- ANXA1
- APEX1
- CYGB
- DAPK1
- EFEMP1
- Halling 4 marker LAVysion lung cancer probe set
- Hanash 3 marker panel for Lung Cancer
- LAMR1
- MPG
- OGG1
- PARK7
- PGP
- TCF21
- UCHL1
Data Collections
- Start Date
- Sep 5 2006
- Estimated Finish Date
- Jun 1 2009
- Finish Date
- Jun 1 2009
- Protocol ID
- 138
- Protocol Type
- Validation
- Fields of Research
-
- Proteomics
- Collaborative Group
- Lung and Upper Aerodigestive Cancers Research Group
- Cancer Types
-
- Malignant neoplasm of bronchus and lung
- Phased Status
- 2